```html

Nijmegen Breakage Syndrome (NBS) – A Comprehensive Medical Guide

Overview

Nijmegen Breakage Syndrome (NBS) is a rare, autosomal‑recessive primary immunodeficiency disorder that belongs to the group of DNA‑repair diseases. It is caused by mutations in the NPC1L1 (actually NBN) gene, which encodes the protein nibrin—a key component of the MRN complex (MRE11‑RAD50‑NBN) that detects and repairs double‑strand DNA breaks.

The condition was first described in 1981 in a cohort of children from the city of Nijmegen, the Netherlands, hence the name. It is most common in individuals of Slavic descent (particularly from Poland, Russia, Belarus, and Ukraine) where a founder mutation (c.657_661del5) accounts for ~90 % of cases.<sup>[1] Mayo Clinic</sup>

• Prevalence: Approximately 1 in 100,000–200,000 live births worldwide, but up to 1 in 45,000 in certain Eastern‑European populations.<sup>[2] WHO</sup>
• Gender: Both males and females are affected equally, because the mutation is autosomal.
• Age of onset: Signs typically emerge in early childhood (first 2 years), but diagnosis may be delayed until school age when growth failure, facial features, and immune problems become evident.

Symptoms

Because NBS results from defective DNA repair, its clinical picture combines features of a primary immunodeficiency, microcephaly, dysmorphic facial appearance, and a high predisposition to malignancy. Below is a complete symptom list with short descriptions.

Growth‑related findings

• Micro‑microcephaly: Head circumference ≤ 2 SD below the mean, often evident at birth.
• Short stature: Height often < 3rd percentile; growth velocity slows after age 2.
• Low weight: Frequently proportional to height, but some children have failure to thrive.

Facial dysmorphism

• Prominent forehead, epicanthal folds, long palpebral fissures.
• Short nose with a flat nasal bridge.
• Large ears that may be low‑set.
• High‑arched palate and occasional dental crowding.

Immunologic abnormalities

• Recurrent sinopulmonary infections: Otitis media, bronchitis, pneumonia.
• Frequent viral infections: VZV, HSV, EBV.
• Low serum IgG and IgA, variable IgM.
• Reduced numbers of B‑cells and/or T‑cells.

Hematologic findings

• Chromosomal instability visible as “butterfly” breaks on cytogenetic analysis.
• Peripheral cytopenias (anemia, thrombocytopenia) may appear during infections or after chemotherapy.

Neurologic and developmental issues

• Developmental delay, especially speech and fine‑motor skills.
• Learning difficulties; IQ commonly in the borderline range (70–85).
• Occasional seizures (≈ 10 % of patients).

Other organ system involvement

• Gastrointestinal: chronic gastritis, occasional inflammatory bowel disease‑like symptoms.
• Skin: photosensitivity, café‑au‑lait spots, xerosis.
• Increased susceptibility to radiation‑induced damage (e.g., during imaging).

Malignancy predisposition

• Most common: Non‑Hodgkin lymphoma (especially diffuse large B‑cell) and cerebellar medulloblastoma.
• Risk of cancer rises dramatically after puberty; 50 % of patients develop a malignancy by age 20‑30.<sup>[3] NIH</sup>

Causes and Risk Factors

The root cause of NBS is a pathogenic mutation in the NBN gene (previously called nibrin or hMRE11‑RAD50‑NBN complex gene). Most cases involve the founder deletion c.657_661del5, which produces a truncated, non‑functional protein.

• Autosomal‑recessive inheritance: Both parents must carry one defective copy. Carriers are usually asymptomatic.
• Consanguinity: In families where parents are related, the chance of both being carriers increases, raising the risk for affected offspring.
• Ethnic background: Highest carrier frequency in Slavic populations (approx. 1 in 100–150 carriers).<sup>[2] WHO</sup>

Other risk-modifying factors:

• Exposure to ionizing radiation: Because NBN is crucial for DNA damage response, radiation (including medical CT scans) can exacerbate chromosomal breakage and increase cancer risk.
• Environmental mutagens: Tobacco smoke, certain chemicals, and viral oncogenes (e.g., EBV) may act as co‑carcinogens.

Diagnosis

Diagnosing NBS involves a combination of clinical evaluation, laboratory testing, and genetic confirmation.

Clinical suspicion

• Microcephaly + characteristic facial features + recurrent infections.
• Family history of early‑onset cancers or consanguinity.

Laboratory and radiologic studies

• Immunoglobulin panel: Low IgG/IgA, sometimes low IgM.
• Lymphocyte phenotyping: Flow cytometry to assess CD19+ B‑cells, CD3+, CD4+, CD8+ T‑cells.
• Cytogenetic analysis: Peripheral blood cultured with mitogens shows increased chromosomal breaks (≥ 10 % of metaphases).
• Radiologic imaging: MRI/CT of the brain to evaluate for structural anomalies; chest CT for lung disease; however, radiation exposure should be minimized.

Genetic testing

The definitive diagnosis is achieved by sequencing the NBN gene.

• Targeted mutation analysis: Detects the common Slavic founder deletion.
• Full‑gene sequencing or multigene panels: Useful when the founder mutation is absent.
• Carrier testing: Recommended for siblings of an affected child and for couples with a known family history.

Diagnostic criteria (summarized)

1. Presence of microcephaly and facial dysmorphism.
2. Immunodeficiency (reduced Ig levels or lymphocyte counts).
3. Chromosomal instability on cytogenetics.
4. Pathogenic NBN mutation.

Treatment Options

There is currently no cure for NBS; management is multidisciplinary and focuses on infection control, cancer surveillance, and supportive care.

Immunologic management

• Immunoglobulin replacement therapy (IVIG or SCIG): Regular infusions (every 3–4 weeks) raise IgG levels and reduce bacterial infections.<sup>[4] Cleveland Clinic</sup>
• Prophylactic antibiotics: Trimethoprim‑sulfamethoxazole or azithromycin during high‑risk seasons.
• Vaccinations: Inactivated vaccines are safe; live vaccines (e.g., MMR, varicella) are generally contraindicated unless IgG levels are adequate and a physician deems them safe.
• Hematopoietic stem‑cell transplantation (HSCT): Considered for severe combined immunodeficiency phenotype, but carries high risk due to radiosensitivity.

Cancer surveillance & treatment

• Regular screening: Full‑body physical exam every 6 months, abdominal ultrasound, brain MRI (annually after age 10), and complete blood count with differential.
• Low‑dose imaging protocols: Prefer MRI or ultrasound over CT whenever possible.
• Chemotherapy adjustments: When malignancy occurs, dose‑reduced regimens and avoidance of radiotherapy are recommended because of DNA‑repair defects.
• Targeted therapies: Clinical trials of PARP inhibitors are under investigation, given the DNA‑repair pathway involvement.

Growth and developmental support

• Endocrinology referral for growth hormone assessment; short stature may respond modestly to GH if IGF‑1 axis is intact.
• Early intervention services: speech therapy, occupational therapy, and individualized education plans (IEPs).
• Nutrition counseling to address failure to thrive.

Lifestyle and supportive measures

• Hand‑washing, mask use during viral seasons, and avoidance of crowded indoor settings to limit infections.
• Dental hygiene program to prevent oral infections.
• Psychological support for patient and family—coping with chronic illness and cancer anxiety.

Living with Nijmegen Breakage Syndrome

Successful long‑term management hinges on a structured daily routine and coordinated care.

Practical tips for patients and families

• Maintain a health diary: Record infections, fevers, medication doses, and any new skin lesions.
• Schedule regular follow‑ups: Immunology (every 3–6 months), oncology (semi‑annually), and genetics (as needed).
• Vaccination calendar: Keep a copy of administered vaccines; avoid live vaccines unless cleared.
• School accommodations: 504 plans or IEPs for extra time, reduced exposure to sick classmates, and access to a private restroom.
• Travel precautions: Carry a letter detailing the diagnosis, a supply of IVIG/antibiotics, and a list of nearby hospitals.
• Support networks: Join rare‑disease groups (e.g., NBS Foundation, European Society for Immunodeficiencies) for peer support and updates on research.

Psychosocial considerations

Children with NBS often experience social isolation due to frequent illness. Encouraging virtual socialization, hobby development, and involving mental‑health professionals can improve quality of life.

Prevention

Because NBS is genetic, primary prevention is limited to carrier awareness and reproductive counseling.

• Carrier screening: Recommended for couples of known Slavic ancestry or with a family history of NBS.
• Pre‑implantation genetic diagnosis (PGD): For couples undergoing in‑vitro fertilization, embryos can be tested for the NBN mutation.
• Prenatal testing: Chorionic villus sampling or amniocentesis can detect the mutation if parents are known carriers.
• Environmental risk reduction: Minimize exposure to ionizing radiation (limit CT scans) and avoid known carcinogens (tobacco smoke, excessive UV sunlight).

Complications

If left untreated or poorly managed, NBS can lead to serious, sometimes life‑threatening complications.

• Severe, recurrent infections: May progress to chronic lung disease (bronchiectasis) or sepsis.
• Malignancies: Lymphomas and medulloblastoma are the most common; advanced cancers have poorer outcomes in NBS due to treatment limitations.
• Progressive neurocognitive decline: Uncontrolled infections and chronic inflammation can aggravate learning deficits.
• Hematologic abnormalities: Bone‑marrow failure or aplastic anemia secondary to DNA instability.
• Radiation‑induced toxicity: Standard radiotherapy can cause severe tissue injury, secondary malignancies, or organ failure.

When to Seek Emergency Care

---

References (accessed May 2026):

1. Mayo Clinic. “Nijmegen breakage syndrome.” https://www.mayoclinic.org/
2. World Health Organization. “Rare diseases: an overview.” WHO Rare Diseases Fact Sheet, 2023.
3. National Institutes of Health (NIH). “Nijmegen Breakage Syndrome – Genetic and Clinical Features.” https://www.ncbi.nlm.nih.gov/
4. Cleveland Clinic. “Immunoglobulin Replacement Therapy.” 2024 guidelines.
5. European Society for Immunodeficiencies (ESID) Registry Annual Report, 2022.

```